Mesoblast Limited AI Stock Analysis
Mesoblast Limited (LWB) AI Stock Analysis
Mesoblast Limited
(Frankfurt:LWB)
No summary available
Mesoblast Limited (LWB) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 1.48B
- Dividend Yield
- ―
- Average Volume (3M)
- 2,078
- Price to Earnings (P/E)
- -29.4
- Beta (1Y)
- 0.98
- Revenue Growth
- 553.65%
- EPS Growth
- 51.03%
- Country
- Germany
- Employees
- 108
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Mesoblast Limited Business Overview & Revenue Model
Company Description
Mesoblast Limited, an Australian enterprise established in Melbourne in 2004, is dedicated to developing innovative regenerative medicine products. The company's global reach extends to the United States, Singapore, the United Kingdom, and Switzerlan...
Mesoblast Limited Earnings Call Summary
The call communicated strong commercial momentum from the Ryoncil launch (USD 49M H1 revenue), industry-leading gross margins (93%), broad payer coverage, rapid center onboarding and multiple near-term regulatory and clinical milestones (Revascor BLA next quarter; back pain enrollment completion and 2027 BLA). The company also strengthened its balance sheet with USD 130M cash and a USD 125M credit facility. Offsetting risks include a sharp increase in R&D and SG&A spending, reliance on Ryoncil for most revenues, ongoing manufacturing/CMC items ahead of filings, and near-term cash usage (USD 30.3M H1) with a tranche deadline in June 2026. Overall, the positive operational, clinical and financial developments materially outweigh the execution and expense risks.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management reiterated FY2026 guidance and laid out key metrics: H1 revenues were $51.3M with Ryoncil net product revenues of $49M and a 93% gross margin (gross margin excl. amortization ~$44.2M); direct selling costs $7.7M, R&D $46.2M, SG&A $28.5M, net loss $40.2M, and H1 operating cash use $30.3M. Cash was $130M at Dec 31 and Mesoblast has a $125M credit facility (first tranche $75M drawn, $50M available through June 2026); the subordinated royalty facility is expected to be fully repaid by mid‑2026 and operating cash use is expected to decline in H2. For Ryoncil they expect full‑year net revenues of $110–120M, target ~20% pediatric penetration by year‑end (based on a ~375‑patient base and a 40% peak‑share assumption), have onboarded 49 centers (30 with formulary listings; 13 using Optum Frontier), secured coverage for >280M lives with Medicaid in all states and J‑code J3402 effective Oct 1, and plan label expansion into adults (market ~3x pediatric). Pipeline milestones include rexlemestrocel‑L (404‑patient Phase III completed; confirmatory 300‑patient trial enrolling with enrollment expected by Mar/Apr and a 2027 data/BLA timeline) and Revascor (LVAD II: 159‑patient 2:1 RCT plus supportive 30‑patient study showing ~5‑fold reduction in major bleeding through 12 months and survival benefit) with a BLA filing for full approval planned next quarter.
Mesoblast Limited Risk Analysis
Mesoblast Limited disclosed 80 risk factors in its most recent earnings report. Mesoblast Limited reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksMesoblast Limited Peers Comparison
Overall Rating
AU:TRP47Neutral
AU:OCC44Neutral
AU:CYP43Neutral
AU:1AI40Underperform
AU:CMB39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 47Neutral | AUD 5.86M | -1.24 | -52.04% | ― | 32.22% | -26.53% | |
| 44Neutral | AUD 152.54M | -10.47 | -36.83% | ― | 51.07% | -47.63% | |
| 43Neutral | AUD 4.35M | -0.36 | -617.89% | ― | ― | 13.67% | |
| 40Underperform | AUD 18.25M | -5.14 | -132.20% | ― | ― | -200.00% | |
| 39Underperform | AUD 10.60M | -1.43 | -247.44% | ― | -4.24% | 33.39% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:LWB | Mesoblast Limited | 1.17 | -0.03 | -2.50% | |
| AU:CYP | Cynata Therapeutics Limited | 0.01 | -0.22 | -94.47% | |
| AU:1AI | Living Cell Technologies Ltd. | 0.01 | 0.00 | 0.00% | |
| AU:OCC | Orthocell Ltd | 0.56 | -0.42 | -42.86% | |
| AU:TRP | Tissue Repair Ltd | 0.11 | -0.18 | -62.07% | |
| AU:CMB | Regeneus Ltd. | 0.36 | -0.15 | -29.41% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
